AbbVie (ABBV) Share-based Compensation (2012 - 2026)

AbbVie (ABBV) has 15 years of Share-based Compensation data on file, last reported at $444.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $444.0 million, up 8.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $989.0 million (up 1.64% YoY), and the FY2025 annual result was $955.0 million, up 4.83% from the prior year.
• Share-based Compensation rose to $444.0 million in Q1 2026 per ABBV's latest filing, from $157.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $444.0 million in Q1 2026 and troughed at $107.0 million in Q2 2022.
• A 5-year average of $219.3 million and a median of $179.0 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation tumbled 32.7% in 2022, then soared 67.29% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $132.0 million in 2022, then retreated by 5.3% to $125.0 million in 2023, then soared by 31.2% to $164.0 million in 2024, then declined by 4.27% to $157.0 million in 2025, then surged by 182.8% to $444.0 million in 2026.
• Business Quant data shows ABBV's Share-based Compensation at $444.0 million in Q1 2026, $157.0 million in Q4 2025, and $209.0 million in Q3 2025.